It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

In-home injection training

Sandoz One Source offers in-home visits where a nurse trainer provides eligible patients detailed instructions on the administration of ZIEXTENZO. Training via video and telephone are also available.

Step 1. Prior to the visit, Sandoz One Source will provide you with educational supplies and materials. Step 2. Suring the visit, your nurse trainer will give you tips to improve your injection experience. Step 3. At the end of the visit, your nurse trainer will make sure you have met all the requirements so you feel comfortable with self-administration.

Call Sandoz One Source at 1-844-SANDOZ1 (1-844-726-3691) to find out more.

If eligible, you can receive your first and subsequent doses of ZIEXTENZO at no cost.

Commercial Co-Pay Program for ZIEXTENZO

The Sandoz One Source Commercial Co-Pay Program for ZIEXTENZO supports eligible,* commercially insured patients with their out-of-pocket co-pay costs for ZIEXTENZO.

Learn more about $0 out-of-pocket for first dose or cycle. $0 out-of-pocket for subsequent doses or cycles.

Two easy ways to enroll

  • Call Sandoz One Source at 1-844-SANDOZ1 (1-844-726-3691)
  • Submit an online Sandoz One Source enrollment form
Online co-pay enrollment

Other support services

Learn about additional ZIEXTENZO support services

Sandoz One Source provides comprehensive support services designed to help simplify and support patient access.

  • Benefit investigations
  • Prior authorization support
  • Appeals support
  • Independent foundation information
  • Patient Assistance Program
  • Reimbursement support
SANDOZ one source contact information.

Contact Sandoz One Source

Call Sandoz One Source to enroll in support services
Fax Sandoz One Source to enroll in support services

*Eligibility Requirements: Maximum benefit of $10,000 annually. Prescription must be for an approved indication. This program is not health insurance. This program is for insured patients only; cash-paying or uninsured patients are not eligible. Patients are not eligible if prescription for ZIEXTENZO is paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TRICARE, or private indemnity plans that do not cover prescription drugs, or HMO insurance plans that reimburse the patient for the entire cost of their prescription drugs, or where prohibited by law. Co-Pay Program may apply to out-of-pocket expenses that occurred within 120 days prior to the date of the enrollment. Co-Pay Program may not be combined with any other rebate, coupon, or offer. Co-Pay Program has no cash value. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.

Still have questions?

Important Safety Information

Do not take Ziextenzo® if you have had a serious allergic reaction to pegfilgrastim or filgrastim.

Before you receive Ziextenzo®, tell your healthcare provider about all of your healthcare conditions, including if you:

  • Have a sickle cell disorder
  • Have kidney problems
  • Are allergic to latex—The needle cap on the prefilled syringe contains dry natural rubber (made from latex).
  • Are pregnant or plan to become pregnant. It is not known if Ziextenzo® will harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if Ziextenzo® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible serious side effects of Ziextenzo®?

  • Spleen Rupture. Your spleen may become enlarged and can rupture. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or your left shoulder.
  • A serious lung problem called Acute Respiratory Distress Syndrome (ARDS). Call your healthcare provider or get emergency medical help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.
  • Serious Allergic Reactions. Ziextenzo® can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate and sweating. If you have any of these symptoms, stop using Ziextenzo® and call your healthcare provider or get emergency medical help right away.
  • Sickle Cell Crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive Ziextenzo®. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.
  • Kidney injury (glomerulonephritis). Ziextenzo® can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms:
    • swelling of your face or ankles
    • blood in your urine or dark colored urine
    • urinate less than usual
  • Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with Ziextenzo®.
  • Decreased platelet count (thrombocytopenia). Your healthcare provider will check your blood during treatment with ZIEXTENZO. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with ZIEXTENZO. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot.
  • Capillary Leak Syndrome. Ziextenzo® can cause fluid to leak from blood vessels into your body's tissues. This condition is called "Capillary Leak Syndrome" (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:
    • swelling or puffiness and are urinating less than usual
    • trouble breathing
    • swelling of your stomach area (abdomen) and feeling of fullness
    • dizziness or feeling faint
    • a general feeling of tiredness
  • Myelodysplastic syndrome and acute myeloid leukemia. If you have breast cancer or lung cancer, when ZIEXTENZO is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with ZIEXTENZO.
  • Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received pegfilgrastim. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms.

The most common side effect of Ziextenzo® is pain in your bones, arms, and legs.

These are not all the possible side effects of Ziextenzo®. Call your healthcare provider for medical advice about side effects. To report negative side effects, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

What is Ziextenzo?

Ziextenzo® is a man-made form of granulocyte colony-stimulating factor (G-CSF). G-CSF is a substance produced by the body. It stimulates the growth of neutrophils, a type of white blood cell important in the body’s fight against infection.

Please see ZIEXTENZO full Prescribing Information  and  Patient Information.

Sandoz: A division of Novartis logo

ZIEXTENZO, Zarxio, and the Sandoz One Source logo are registered trademarks of Novartis AG.
© 2021 Sandoz Inc. 100 College Road West, Princeton, NJ 08540. All Rights Reserved.
S-ZIE-1383831 05/2021